TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01496378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving Skills Training
Description: Parents will receive 8, 1-hour sessions of individual problem-solving therapy over 8 weeks. Caregivers will complete the first training session and at least 3 subsequent sessions in person. Remaining sessions will be completed via telephone. In session 1, parents will be introduced to the PSST program and a rationale and explanation for problem solving strategies will be provided. During sessions 2-8, parents will identify a problem that they wish to work on. The therapist will use the primary cognitive-behavioral strategies of modeling, behavioral rehearsal, performance feedback, and generalization of skills in the process of teaching problem solving skills to parents. Parents will complete homework assignments to practice using the problem-solving skills in real-life situations
Study: NCT00327873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: 2L/min for 15 hours or greater per day via concentrator and nasal cannulae for 7 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Air
Description: 2L/min for 15 hours or greater per day via concentrator and nasal cannulae for 7 days
Study: NCT04767074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-pharmacological Cough control Therapy
Description: Participants will attend four virtual sessions of 45 to 60 minutes of educational and self-management.~Session 1 General assessment Prescription and taught of one cough suppression technique.~Session 2 Cough principles: mechanism, cough reflex, chronic cough, the importance of cough and negative effects of repeated coughing.~Cough control: identify triggers, use cough suppressions and distractions techniques.~Session 3 Breathing pattern retraining and laryngeal hygiene: reinforce nasal breathing and pursed lips breathing as strategies to avoid the urge to cough, identification of risk factors for laryngeal dehydration and hydration education.~Session 4 Reinforcement: Clarification of doubts, techniques' reinforcement and application during daily life situations.
Study: NCT02958956

Intervention type: DRUG
Intervention: Pioglitazone
Description: Participants with diabetes who were members of the KPNC registry, and had received at least 2 prescriptions for pioglitazone within a 6-month period were followed up to 15.5 years (1997-2012) in this observational study 1.
Study: NCT00953979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: kunxian capsule
Description: The main element of kunxian capsule is Tripterygium. Patients should take 2 tablets per time and 3 times per day for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: kunxian capsule
Description: The main element of kunxian capsule is Tripterygium. Patients should take 2 tablets per time and 3 times per day for 12 weeks.
Study: NCT06217237

Intervention type: DIAGNOSTIC_TEST
Intervention: AD FDT DBL GROUP
Description: All participants will undergo an MRI session. The MRI protocol will include the clinical diagnostic protocol defined within the Network and research sequences as specified above (T1 3D, DTI, FLAIR 3D, QSM).
Study: NCT01506323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mantram Repetition Program (MRP)
Description: The MRP teaches three portable, mindfulness strategies to train attention and manage symptoms: 1) Mantram (sacred word) Repetition, 2) Slowing Down, and 3) One-Pointed Attention. These tools are presented as working together synergistically and cumulatively, over time, to interrupt negative thoughts, behaviors, and emotional states such as anger, rage, irritability and impatience. Participants choose their own words or phrases and are encouraged to practice repeating a mantram at any time or place. In this study, MRP is delivered individually in eight weekly, 1-hour sessions, using a standardized manual, instructor guide, and homework assignments for experiential learning.
Study: NCT04443075

Intervention type: DEVICE
Intervention: faecal sample collector
Description: The frontline medical workers mainly exposed under the stress of fighting against 2019-nCoV
Study: NCT01506323

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Therapy (PCT)
Description: The PCT is a form of individual therapy that is problem-oriented to improve current coping. It avoids details of traumatic experiences. In this study, it is delivered individually in 8 weekly, 1 hour sessions to serve as an active, attention control arm. Sessions are unstructured and managed so that there is some engagement of the participant's emotional concerns with an emphasis on strengths and process encouragement rather than skills training. Three components of PCT include 1) developing a therapeutic relationship for social support, 2) focusing on current problems and problem solving, 3) and setting goals.
Study: NCT04011969

Intervention type: DIAGNOSTIC_TEST
Intervention: Score assessment
Description: Asia Pacific Colorectal Screening (APCS) is a validated tool to predict the risk of colorectal cancer in asymptomatic Asian population. The scoring system comprises of three categories: low risk (score 0-1), moderate risk (score 2-3) and high risk (score 4-7). Patients with moderate and high risk will undergo further examinations.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Blood samples will be taken before colonoscopy procedure to evaluate the level of serum CEA by ELISA method and to evaluate the presence of NF-ҡB by immunohistochemical method.~1. Carcinoembryonic antigen (CEA) is a well-known marker for colorectal cancer. A pre-treatment serum CEA level of ≥ 5 ng/mL is associated with poor prognosis in colorectal cancer patients.~2. NF-ҡB is a chronic inflammation marker found in colorectal cancer patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal sampling
Description: Fecal samples will be taken before colonoscopy procedure to be tested for FIT and to evaluate the gut microbiome.~1. Fecal immunochemical test (FIT) is a recommended screening method for colorectal cancer. Detection of hemoglobin over a certain level in fecal samples indicated a positive FIT. Patients with positive FIT will undergo further examinations.~2. Gut microbiome examination will be conducted with next generation sequencing (NGS) method.
Study: NCT04579328

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to Growth Mats
Description: see arm/group descriptions for description of intervention
Study: NCT02473328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir 200 mg/r
Description: 1. In patients signed an informed consent and meeting all the eligibility criteria at the time of the run-in (S-4),~2. switch of antiretroviral therapy Atazanavir 300 mg/ritonavir 100 mg once a day to Atazanavir 200 mg/ritonavir 100 mg once a day without changing the combination of 2 NRTIs associated.~The administration will be done once a day orally for 48 weeks.~The usual recommended dose of atazanavir is 300 mg once daily with 100 mg of ritonavir once daily with food. Ritonavir acts by potentiating the pharmacokinetics of atazanavir.
Study: NCT01996579

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: Lactoferrin is an 80 kilodalton (kD) naturally occurring multifunctional glycoprotein of the transferrin family which is an important component of the human innate immune system. Lactoferrin is distributed widely in humans with the main sources of production being exocrine glands and specific granules of neutrophils. It is present in virtually all human secretions. The highest concentrations are found in milk and colostrum. Lactoferrin has multiple biological functions which make it of interest as a therapeutic agent in the critically ill. These include the ability to bind iron, antimicrobial activity including antibacterial, antifungal, antiviral properties, the ability to bind endotoxin, promotion of beneficial bacteria in the gastro-intestinal tract and immunomodulatory activity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile water will be utilized as the placebo control in this double blind randomized-controlled trial.
Study: NCT02048072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilenya
Description: Autonomic testing during first dose administration of Gilenya.
Study: NCT01080508

Intervention type: OTHER
Intervention: tracheal ventilation with regular tube
Description: Description of the pressure waveforms during tracheal ventilation
Study: NCT04000438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF01
Description: The subject receives sc injections of tafoxiparin solution once daily for up to 7 days until labor induction or spontaneous onset of labor. Induction is done according to clinical practice; 1st balloon, 2nd PGE1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF01
Description: The subject receives sc injections of tafoxiparin solution once daily for up to 7 days until labor induction or spontaneous onset of labor. Induction is done according to clinical practice; 1st balloon, 2nd PGE1
Study: NCT01080508

Intervention type: OTHER
Intervention: ventilation after intubation with special tube
Description: Description of the pressure waveforms during esophageal ventilation
Study: NCT01342705

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phlebotomy
Description: Procedure: Phlebotomy of 4 ml / kg to obtain (1 phlebotomy every 14 days) and maintain (1 phlebotomy every 3 months) a serum ferritin below 50 µg / l.
Study: NCT03655795

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bronchial basal cells
Description: Autologous transplantation of bronchial basal cells
Study: NCT01779726

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT scan before chest physician
Description: Patients referred to department of lung medicine are randomised according to the month of birth. Patients born in even months are CT scan before a consultation with a chest physician

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Usual diagnostic workup
Description: Patients born in odd months seen in the department of lung medicine by a chest physician and maybe then CT scanned (usual workup practice according to the fast track evaluation)
Study: NCT04000438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF01
Description: The subject receives sc injections of tafoxiparin solution once daily for up to 7 days until labor induction or spontaneous onset of labor. Induction is done according to clinical practice; 1st balloon, 2nd PGE1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PL1
Description: The subject receives sc injections once daily of placebo solution for up to 7 days until labor induction or spontaneous onset of labor. Induction is done according to clinical practice; 1st balloon, 2nd PGE1
Study: NCT02718989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Stimulation
Description: TENS transcutaneous electrical stimulation over the back the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Stimulation
Description: TENS transcutaneous electrical stimulation over the back the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10Kilohertz (KHz)
Description: 10 KHz transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
Study: NCT00505960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Care for Korean Americans
Description: Intervention group participants receive a 6-week in-class education offered by trained nurses, followed by home glucose monitoring with monthly nurse telephone counseling.
Study: NCT00789256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan: 2mg orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib: 1.0mg/M2 IV on days 1, 4, 8, 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan and bortezomib
Study: NCT05251831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intradermal injection
Description: Platelet-rich plasma (PRP) therapy uses injections of a concentration of a patient's own platelets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intradermal injection
Description: Platelet-rich plasma (PRP) therapy uses injections of a concentration of a patient's own platelets.
Study: NCT02064712

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low CPAP Wean
Description: Infants receive NCPAP by Hudson nasal prongs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High CPAP Wean
Description: Infants receive NCPAP by Hudson nasal prongs.
Study: NCT03220282

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Donor milk
Description: For late preterm newborns who are breastfeeding and whose mothers are not making enough breast milk yet to meet their nutritional needs, the study will compare the intervention of banked donor breast milk with the control of preterm infant formula.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Preterm infant formula
Description: Preterm formula determined by clinical practice
Study: NCT05034198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Power Program (CPP)
Description: CPP is an evidence-based intervention designed for students with externalizing behavior disorder. CPP consists of twelve 45-minute sessions. This EBP has been found to be effective at reducing aggressive behavior, covert delinquent behavior and substance abuse among aggressive boys, with gains maintained at one-year follow-up. Growth curve analyses showed that CPP had linear effects for three years after intervention on reductions in aggressive behavior and academic behavior problems.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) for Anxiety Treatment in Schools (CATS)
Description: CATS is an adaptation of Friends for Life (FRIENDS). The adapted protocol retains the core elements of evidence-based CBT for anxiety and the FRIENDS group format. Investigators implemented planned adaptations to the protocol based on collective experience. Changes were made to the language, cultural methods, number of sessions, and activities while maintaining the 5 essential components of the treatment. This resulted in a briefer (8-session) and more feasible, engaging and culturally appropriate protocol for urban under-resourced schools than the original FRIENDS.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check-in/Check-out (CI/CO)
Description: CI/CO is a targeted, Tier 2 intervention for students at risk of developing externalizing and internalizing mental health disorders. CI/CO is designed to provide immediate feedback (i.e., at the end of each class period) to students, based on the use of a daily report card. This feedback is developmentally sensitive. CI/CO implementers meet individually with students for a brief 'check-in' in the morning and a brief 'check-out' in the afternoon. Research on the use of CI/CO has shown it to be effective in reducing externalizing and internalizing problems with elementary school students. CI/CO will be offered to individual students for a three-month period of time, which is the same time-frame needed for the implementation of CPP.
Study: NCT02469688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4070
Description: intramuscular or intradermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4070
Description: intramuscular or intradermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4070
Description: intramuscular or intradermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4070
Description: intramuscular or intradermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4070
Description: intramuscular or intradermal
Study: NCT01529125

Intervention type: DRUG
Intervention: zidovudine, lamivudine, nevirapine

Intervention type: DRUG
Intervention: zidovudine, lamivudine, nevirapine

Intervention type: DRUG
Intervention: zidovudine, lamivudine, nevirapine
Study: NCT03660579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT-AB Group
Description: Group that performed HIIT and consumed 330 ml (women) or 2x300 ml (men) of beer with 5.4% alcohol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT-NAB Group
Description: Group that performed HIIT and consumed 330 ml (women) or 2x300 ml (men) of beer without alcohol (0.0%).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT-SW Group
Description: Group that performed HIIT and consumed the same amount of sparkling water (0.0%).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT-ASW Group
Description: Group that performed HIIT and consumed sparkling water with the same amount of alcohol than the pre-established beer (5.4%).
Study: NCT02075879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led interviewing
Description: Participants in experimental arm received regular face-to-face interviews during dialysis sessions conducted by the designated case managers every week for 6 weeks and biweekly for another 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief group exercise
Description: Participants in this arm only participated in the brief in-center exercise training. They received usual care from the nurse without the interviews and mutual goals developed.
Study: NCT01971723

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: T+ Supplement
Description: Randomized, placebo-controlled, double blind protocol with two treatment groups (matched by lean body mass). Group 1 will receive the recommended serving of one scoop (11g) of T+ supplement. This serving will be taken 45 minutes before the beginning of working out on an empty stomach (\>1 hour after meal). On non-training days, the participants will also take a serving at the same time as on training days. This will continue for four weeks (28 days).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will consume a calorie-match placebo in the same manner as the supplement group (one serving 45 minutes prior to work outs on an empty stomach). The placebo group will also follow the same supplementation patterns and workout as their counterparts in the supplement group.
Study: NCT01778348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Overnight closed-loop
Description: The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real-time CGM alone
Description: Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
Study: NCT02469688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4070
Description: intramuscular or intradermal
Study: NCT03055143

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPARC-08-038
Description: 2 mg/ml intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC-08-038
Description: 2 mg/ml intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ref-08-038
Description: 2 mg/ml intravenous infusion
Study: NCT02469688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4070
Description: intramuscular or intradermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4070
Description: intramuscular or intradermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intramuscular or intradermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intramuscular or intradermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intramuscular or intradermal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intramuscular or intradermal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intramuscular or intradermal
Study: NCT03055143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ref-08-038
Description: 2 mg/ml intravenous infusion
Study: NCT02600728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Training
Description: The ET consisted of 3 phases being that the first one (Phase 1) was done only in the first session.~Phase 1: patients received a short and simple explanation about the deficiency in automatic movement resulting from PD. Following explanation, the patient memorized a sequence of declarative cues. Phase 2: the patient organized a sequence of cues using cards illustrating the subcomponent movements (key movement) involved in taking steps.~Phase 3: the patient had to train using declarative cues as a gait performance aid through 8 sets follow the instruction Walk in your ordinary speed. Use the key movements and going to saying each of them while you make them. The declarative cues had to be evoked verbally by the patients themselves, during gait, triggering the corresponding movement.
Study: NCT02090530

Intervention type: OTHER
Intervention: Biospecimen collection
Description: Specimens to be collected include a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.
Study: NCT02600728

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Training
Description: The CT consisted of 3 phases, being the first one (Phase 1) was done only in the first session of training, and the other two (Phase 2 and 3) were repeated at each of the 8 sessions.~Phase 1: Patients received a short and simple explanation about the deficiency in automatic movement resulting from PD.~Phase 2: Patients received a general verbal attentional instruction of pay attention to your steps and try to walk as better as you can, before starting the walk.~Phase 3: motor training of gait, where the patient had to perform 8 sets, following the instruction Walk in your ordinary speed, paying attention to your steps in the identical trajectories of ET. Additional instructions or cues were not provided.